These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 24568571)

  • 1. Routine administration of Anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice.
    Kent J; Farrell AM; Soothill P
    BMC Pregnancy Childbirth; 2014 Feb; 14():87. PubMed ID: 24568571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS.
    Soothill PW; Finning K; Latham T; Wreford-Bush T; Ford J; Daniels G
    BJOG; 2015 Nov; 122(12):1682-6. PubMed ID: 25142171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
    Daniels G; Finning K; Martin P; Summers J
    Transfus Clin Biol; 2007 Dec; 14(6):568-71. PubMed ID: 18436463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
    Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
    Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
    Szczepura A; Osipenko L; Freeman K
    BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antenatal
    Clausen FB
    Immunohematology; 2024 Apr; 40(1):15-27. PubMed ID: 38739027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
    Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
    BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of fetal RHD type in plasma of RhD negative pregnant women.
    Sørensen K; Kjeldsen-Kragh J; Husby H; Akkök ÇA
    Scand J Clin Lab Invest; 2018 Sep; 78(5):411-416. PubMed ID: 29869532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Antenatal Screening for Fetal RHD in RhD Negative Women to Guide Targeted Anti-D Prophylaxis.
    Clausen FB; Rieneck K; Krog GR; Bundgaard BS; Dziegiel MH
    Methods Mol Biol; 2019; 1885():347-359. PubMed ID: 30506209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RHD genotyping from maternal plasma: guidelines and technical challenges.
    Avent ND
    Methods Mol Biol; 2008; 444():185-201. PubMed ID: 18425481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine testing of fetal Rhesus D status in Rhesus D negative women using cell-free fetal DNA: an investigation into the preferences and information needs of women.
    Oxenford K; Silcock C; Hill M; Chitty L
    Prenat Diagn; 2013 Jul; 33(7):688-94. PubMed ID: 23625761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review.
    Runkel B; Bein G; Sieben W; Sow D; Polus S; Fleer D
    BMC Pregnancy Childbirth; 2020 Feb; 20(1):83. PubMed ID: 32033599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2020; 20(15):1-160. PubMed ID: 33240456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
    Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
    BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Foetal Rhesus-D typing added to antenatal screening for infectious diseases and erythrocyte immunisation].
    van der Ploeg CP; Hirschberg HJ; de Haas M; Abbink F
    Ned Tijdschr Geneeskd; 2015; 159():A8315. PubMed ID: 25898866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
    Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
    Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive fetal RhD genotyping.
    Clausen FB; Damkjær MB; Dziegiel MH
    Transfus Apher Sci; 2014 Apr; 50(2):154-62. PubMed ID: 24642067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD.
    Clausen FB; Jakobsen TR; Rieneck K; Krog GR; Nielsen LK; Tabor A; Dziegiel MH
    PLoS One; 2013; 8(10):e76990. PubMed ID: 24204719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fetal RHD genotyping by PCR using plasma from D negative pregnant women].
    Achargui S; Tijane M; Benchemsi N
    Transfus Clin Biol; 2011 Feb; 18(1):13-9. PubMed ID: 21190884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.